NCT06143436

Brief Summary

Recently, TCM has played an important role in adjuvant therapy for lung cancer. TCM treatment is based on pattern identification, and constitution theory is also used as a tool for TCM to predict the disease progression. Although there have been many researchs related to the pattern identification and constitution of lung cancer, in view of the problems and limitations, further research on lung cancer patients in Taiwan is needed. This study aims to explore the correlation between TCM constitution, pattern identification, and other related factors in patients with primary lung cancer in Taiwan, hoping to reveal the disease characteristics of lung cancer in TCM theory. This study intends to interview subjects through attending physicians in the thoracic ward and outpatient clinic of the CMUH from November 20th, 2023 to May 19th , 2025, and the subjects will be included in this study after the researchers ask the subjects for consent. This study will collect the demographic data of the subjects (sex, age, BMI, smoking history) and disease-related clinical data (tumor stage, pathological type, gene mutation, tumor markers, other comorbidities), and the investigator will ask about the subjects' signs according to the Constitution in Chinese Medicine Questionnaire (CCMQ) , ask the subjects' symptoms according to the pattern identification table, obtain the data to analyze their distribution by descriptive statistics, and then analyze the correlation between them by analysis of variance and Chi-square test.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 16, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 22, 2023

Completed
28 days until next milestone

Study Start

First participant enrolled

December 20, 2023

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 19, 2025

Completed
Last Updated

January 2, 2024

Status Verified

December 1, 2023

Enrollment Period

1.4 years

First QC Date

November 16, 2023

Last Update Submit

December 28, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • TCM body constitution

    Ask about the subjects' signs according to the Constitution in Chinese Medicine Questionnaire (CCMQ)

    20-30 minuts

  • TCM pattern types

    Ask about the subjects' symptoms according to the pattern identification table

    20-30 minuts

Secondary Outcomes (2)

  • demographic data

    1 day

  • disease-related clinical data

    1 day

Interventions

Using questionnaire to collect data from new lung cancer patients.

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who have been diagnosed with primary lung cancer without any treatment.

You may qualify if:

  • Patients diagnosed with primary lung cancer.
  • Age greater than 18 years and less than 100 years.
  • After explanation, they agree to join this study and voluntarily sign the subject consent form, and can understand the content of the questionnaire.

You may not qualify if:

  • Pregnant women.
  • Severe mental illness that affects the response to the questionnaire.
  • Has been treated (e.g., surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, etc.).
  • Concomitant with other uncured primary malignancies.
  • Patients with other serious primary diseases (such as: liver and kidney dysfunction, hematolymphatic system diseases, etc.).
  • Severe respiratory diseases that are not lung cancer (e.g. primary emphysema, interstitial fibrosis, etc.) .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University Hospital

Taichung, Taiwan

RECRUITING

MeSH Terms

Conditions

Syndrome

Condition Hierarchy (Ancestors)

DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 16, 2023

First Posted

November 22, 2023

Study Start

December 20, 2023

Primary Completion

May 19, 2025

Study Completion

May 19, 2025

Last Updated

January 2, 2024

Record last verified: 2023-12

Locations